May 13, 2020
Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
May 07, 2020
Arena Announces Corporate Update and Reports First Quarter 2020 Financial Results
May 06, 2020
Arena Pharmaceuticals to Present at the Bank of America Securities Healthcare Conference on May 13
Apr 30, 2020
Arena Pharmaceuticals to Release First Quarter 2020 Financial Results and Provide Corporate Update on May 7
Apr 24, 2020
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 30, 2020
Arena Pharmaceuticals Names James C. Mullen as an Independent Senior Advisor
Feb 21, 2020
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 20, 2020
Arena Pharmaceuticals to Present at the Upcoming Investor Conferences
Feb 11, 2020
Arena Pharmaceuticals' Presence at the European Crohn's and Colitis Organisation (ECCO) Congress Further Highlights Commitment to the GI Community
Jan 16, 2020
FDA Grants Fast Track Designation to Arena Pharmaceuticals' APD418 for Development in Decompensated Heart Failure Patients
Jan 13, 2020
Arena Pharmaceuticals Appoints Joan Schmidt as Executive Vice President, General Counsel and Secretary
Jan 08, 2020
Arena Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 16
Jan 02, 2020
Arena Pharmaceuticals and Beacon Discovery Expand Strategic Relationship Focusing on Multiple Immune and Inflammatory Targets
Nov 18, 2019
California Life Sciences Association Honors Arena Pharmaceuticals at the Pantheon 2019 DiNA(TM) Awards for the Deal of the Year
Oct 31, 2019
Arena Pharmaceuticals to Release Third Quarter 2019 Financial Results and Provide Corporate Update on November 7
Oct 28, 2019
Arena Pharmaceuticals Announces First Subject Dosed in ADVISE Phase 2 Trial Evaluating Etrasimod in Atopic Dermatitis
Oct 22, 2019
Arena Pharmaceuticals Presented New Data Analyses Demonstrating the Long-Term Safety and Efficacy of Once-Daily Etrasimod in Patients with Moderately to Severely Active Ulcerative Colitis at UEG Week
Oct 18, 2019
Arena Pharmaceuticals' Presence at United European Gastroenterology Week Bolsters Commitment to the Gastrointestinal Disease Community
Sep 26, 2019
Arena Pharmaceuticals Presented New Data from the Phase 2 OASIS trial for Etrasimod at the World Congress of Gastroenterology Meeting
Sep 09, 2019
Arena Pharmaceuticals Presented New Patient-Reported Outcomes Data for Olorinab at the European Society of Neurogastroenterology & Motility NeuroGASTRO 2019 Meeting